The executive order signed by Trump, focusing on protecting Americans from dangerous gain-of-function research, does not directly address economic or financial policies that typically influence the bond market. However, the order's emphasis on improving the safety and security of biological research could have indirect implications for sectors related to biotechnology and healthcare, which in turn could affect related bonds. Given the lack of direct economic or financial policy implications, the bond market is likely to remain unaffected in the short term. Historical patterns suggest that Trump's statements and actions on national security and public health have not significantly impacted bond yields or prices, unless they have broader economic implications. Therefore, a neutral sentiment score is assigned, reflecting the minimal expected impact of this executive order on the bond market. The bond market's reaction will likely be driven by other economic factors such as inflation, interest rates, and GDP growth, rather than this specific order.